journal article·2018-09Open access

Glycogen-nucleic acid constructs for gene silencing in multicellular tumor spheroids

Marcin Wojnilowicz, Quinn A. Besford, Yun-Long Wu, Xian Jun Loh, Julia A. Braunger, Agata Glab, Christina Cortez-Jugo, Frank Caruso, Francesca Cavalieri

Biomaterials· Volume 176

Abstract

The poor penetration of nanocarrier-siRNA constructs into tumor tissue is a major hurdle for the in vivo efficacy of siRNA therapeutics, where the ability of the constructs to permeate the 3D multicellular matrix is determined by their physicochemical properties. Herein, we optimized the use of soft glycogen nanoparticles for the engineering of glycogen-siRNA constructs that can efficiently penetrate multicellular tumor spheroids and exert a significant gene silencing effect. Glycogen nanoparticles from different bio-sources and with different structural features were investigated. We show that larger glycogen nanoparticles ranging from 50 to 80 nm are suboptimal systems for complexation of nucleic acids if fine control of the size of constructs is required. Our studies suggest that 20 nm glycogen nanoparticles are optimal for complexation and efficient delivery of siRNA. The chemical composition, surface charge, and size of glycogen-siRNA constructs were finely controlled to minimize interactions with serum proteins and allow penetration into 3D multicellular spheroids of human kidney epithelial cells and human prostate cancer cells. We introduced pH sensitive moieties within the construct to enhance early endosome escape and efficiently improve the silencing effect in vitro. Glycogen-siRNA constructs were found to mediate gene silencing in 3D multicellular spheroids causing ∼60% specific gene silencing. The optimized construct exhibited an in vivo circulation lifetime of 8 h in mice, with preferential accumulation in the liver. No accumulation in the kidney, lung, spleen, heart or brain, or signs of toxicity in mice were observed. Our results highlight the potential for screening siRNA nanocarriers in 3D cultured prostate tumor models, thereby improving the predictive therapeutic efficacy of glycogen-based platforms in human physiological conditions.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (59)

Show source-provided references
1. Knocking down disease: a progress report on siRNA therapeutics10.1038/nrg3978 ↗
2. Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics10.1016/j.jconrel.2015.02.003 ↗
3. Systemic siRNA delivery to dendritic cells exploits defence for cancer immunotherapy10.1038/nature18300 ↗
4. RNAi nanomaterials targeting immune cells as an anti-tumor therapy: the missing link in cancer treatment?10.1016/j.mattod.2015.07.005 ↗
5. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer10.1038/nature22341 ↗
6. 15 Years on siRNA delivery: beyond the state-of-the-art on inorganic nanoparticles for RNAi therapeutics10.1016/j.nantod.2015.06.008 ↗
7. Worth the RISC?10.1038/nbt.3810 ↗
8. Recent progress in development of siRNA delivery vehicles for cancer therapy10.1016/j.addr.2016.06.011 ↗
9. Lessons from patient-derived xenografts for better in vivo modeling of human cancer10.1016/j.addr.2014.09.009 ↗
10. Recent advances in siRNA delivery for cancer therapy using smart nanocarriers10.1016/j.drudis.2018.01.042 ↗
11. Delivery is key: lessons learnt from developing splice-switching antisense therapies10.15252/emmm.201607199 ↗
12. Clinical experiences with systematically administrated siRNA-based therapeutics in cancer10.1038/nrd4685 ↗
13. Visualising lipid-formulated siRNA release from endosomes and target gene knockdown
14. Analysis of nanoparticle delivery to tumors10.1038/natrevmats.2016.14 ↗
15. 3D tumor spheroid models for in vitro therapeutic screening: a systematic approach to enhance biological relevance of data obtained10.1038/srep19103 ↗
16. Nanoparticle drug delivery systems and three-dimensional cell cultures in cancer treatments and research10.4103/2395-3977.192933 ↗
17. Spheroid-based drug screen: considerations and practical approach10.1038/nprot.2008.226 ↗
18. Enhanced growth inhibition of hepatic multicellular tumor spheroids by lactosylated poly(ethylene glycol)-siRNA conjugate formulated in PEGylated polyplexes10.1002/cmdc.200700076 ↗
19. Multicellular tumor spheroids as a model for assessing delivery of oligonucleotides in three dimensions10.1038/mtna.2014.5 ↗
20. PAMAM-rgd conjugates enhance siRNA delivery through a multicellular spheroid model of malignant glioma10.1021/bc900228m ↗
21. Spatio-temporal modeling of nanoparticle delivery to multicellular tumor spheroids10.1002/bit.21910 ↗
22. A hydrogel-based tumor model for the evaluation of nanoparticle-based cancer therapies10.1016/j.biomaterials.2013.12.080 ↗
23. Albumin-polymer conjugate nanoparticles and their interactions with prostate cancer cells in 2D and 3D culture: comparison between PMMA and PCL10.1039/C5TB02576A ↗
24. Engineering lipid vesicles of enhanced intratumoral transport capabilities: correlating liposome characteristics with penetration into human prostate tumor spheroids10.1081/LPR-64953 ↗
25. Molar mass and solution conformation of branched alpha(1-4), alpha(1-6) glucans. Part I: glycogens in water10.1016/j.carbpol.2007.05.029 ↗
26. Structure formation by polysaccharides in concentrated solution10.1021/bm0001291 ↗
27. Ultrastructural aspects of phytoglycogen from cryo-transmission electron microscopy and quasi-elastic light scattering data10.1016/S0141-8130(99)00076-8 ↗
28. Nature of alpha and beta particles in glycogen using molecular size distributions10.1021/bm100074p ↗
29. Chemically modified dendritic starch: a novel nanomaterial for siRNA delivery10.1021/acs.bioconjchem.5b00313 ↗
30. Alpha-D-glucan nanoparticulate adjuvant induces a transient inflammatory response at the injection site and targets antigen to migratory dendritic cells10.1038/s41541-017-0007-7 ↗
31. Dendrimer-like alpha-d-glucan nanoparticles activate dendritic cells and are effective vaccine adjuvants10.1016/j.jconrel.2015.03.002 ↗
32. A novel nanoprobe for multimodal imaging is effectively incorporated into human melanoma metastatic cell lines10.3390/ijms160921658 ↗
33. An efficient nonviral gene-delivery vector based on hyperbranched cationic glycogen derivatives
34. Efficient delivery of NF-κb siRNA to human retinal pigment epithelial cells with hyperbranched cationic polysaccharide derivative-based nanoparticles
35. Monocytosis associated with the growth of transplated synergic rat sarcomata differing in immunogenicity10.1038/bjc.1976.116 ↗
36. The significance of macrophages in human and experimental tumors10.1111/j.1749-6632.1976.tb41641.x ↗
37. Lactosylated glycogen nanoparticles for targeting prostate cancer cells10.1021/acsami.7b02676 ↗
38. PRIMUS- a windows-PC based system for small-angle scattering data analysis10.1107/S0021889803012779 ↗
39. Carbohydrate analysis by a phenol-sulfuric acid method in microplate format10.1016/j.ab.2004.12.001 ↗
40. Glycogen as a biodegradable construction nanomaterial for in vivo use10.1002/mabi.201200294 ↗
41. The presence of phosphate in glycogen10.1016/0014-5793(80)81317-2 ↗
42. Glycogen contains phosphodiester groups that can Be introduced by UDPglucose:glycogen glucose 1-phosphate10.1016/0014-5793(93)80234-L ↗
43. Oxidation of glycogen “molecular nanoparticles” by periodate10.1039/C2PY20625K ↗
44. Correlation between chain architecture and hydration water structure in polysaccharides10.1021/acs.biomac.6b00026 ↗
45. Production and characteristics of raw-potato-starch-digesting α-amylase from Bacillus subtilis 6510.1128/aem.54.6.1516-1522.1988 ↗
46. Nanoparticle uptake: the phagocyte problem10.1016/j.nantod.2015.06.006 ↗
47. Principles of nanoparticle design for overcoming biological barriers to drug delivery10.1038/nbt.3330 ↗
48. Nanoparticle-liver interactions: cellular uptake and hepatobiliary elimination10.1016/j.jconrel.2016.01.020 ↗
49. Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane10.1073/pnas.1200718109 ↗
50. Zwitterionic nanocarrier surface chemistry improves siRNA tumor delivery and silencing activity relative to polyethylene glycol10.1021/acsnano.7b01110 ↗
51. How cationic lipids transfer nucleic acids into cells and across cellular membranes: recent advances10.1016/j.jconrel.2012.12.014 ↗
52. Vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis10.1016/S0142-9612(02)00445-3 ↗
53. A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy10.1016/j.ymthe.2005.02.010 ↗
54. Intracellular reafficking of nonviral vectors10.1038/sj.gt.3302592 ↗
55. Nanoescapology: progress toward understanding the endosomal escape of polymeric nanoparticles10.1002/wnan.1452 ↗
56. Glycogen metabolism has a key role in the cancer microenvironment and provides new targets for cancer therapy10.1007/s00109-015-1377-9 ↗
57. Targeting survivin in cancer therapy10.1517/14728222.12.4.463 ↗
58. Ribozyme-mediated down-regulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo10.1093/carcin/bgh107 ↗
59. Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expression10.1046/j.1523-1747.2003.12082.x ↗